2',5'-Dihydroxyacetophenone Clinical Trials

Size	Price	Qty
25mg	USD 97

Clinical Trials

Multiple clinical trials in hematologic oncology are evaluating protocols associated with this compound, primarily targeting relapsed or refractory Hodgkin lymphoma and diffuse large B-cell lymphoma. Sponsored by healthcare institutions and cooperative groups, including the Fondazione Italiana Linfomi, Stichting Hemato-Oncologie voor Volwassenen Nederland, and the National Medical Surgical Center N.A. N.I. Pirogov, these Phase II and combined Phase I/II studies range in recruitment status from actively recruiting to completed or terminated.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04091490	Completed	Hodgkin Lymphoma	State Budgetary Healthcare Institution National Medical Surgical Center N.A. N.I. Pirogov Ministry of Health of Russia	2020-02-19	Phase 2
NCT03356054	Recruiting	DLBCL	Stichting Hemato-Oncologie voor Volwassenen Nederland	2018-03-05	Phase 1\|Phase 2
NCT02374424	Terminated	Diffuse Large B-Cell Lymphoma	Fondazione Italiana Linfomi - ETS	2014-11-05	Phase 2

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the 2',5'-Dihydroxyacetophenone product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

2',5'-Dihydroxyacetophenone suppresses inducible nitric oxide synthase expression and blocks the ERK1/2 and NF-κB signaling pathways, leading to reduced production of nitric oxide and pro-inflammatory cytokines TNF-α and IL-6. This inhibition attenuates inflammatory signal cascades and cellular activation, which provides clinical relevance for modulating tumor microenvironments in lymphoproliferative disorders such as Hodgkin lymphoma and diffuse large B-cell lymphoma.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).